Drug Chatter -- Tracking biopharma stock chatter

Profile for OXiGENE, Inc. (OXGN)

« Back to company index

OXGN Chatter Timeline

Stock Ticker for OXGN

Most Active Tweeters for OXGN

No tweets found

Recent Tweets for OXGN

Allstocknews @Allstocknews
$OXGN New SEC Document(s) for Mateon Therapeutics From our Stock News Alerts App
September 11th 2017, 8:09am
Allstocknews @Allstocknews
$OXGN Mateon Therapeutics to Present at the 19th Annual Rodman and Renshaw Global Investment Conference on Se From our Stock News Alerts App
September 6th 2017, 9:09am
MyAlliesTrading @MyAlliesTrading
$OXGN Mateon Therapeutics Announces Results from Second Interim Analysis of CA4P Phase 2/3 FOCUS Study in Plat... https://t.co/H5tpAm6TVn
August 16th 2017, 5:08pm
MyAlliesTrading @MyAlliesTrading
$OXGN Mateon Therapeutics Announces Results from Second Interim Analysis of CA4P Phase 2/3 FOCUS Study in Plat... https://t.co/7gYXkiVkpk
August 16th 2017, 4:08pm
BioStocks @BioStocks
$MATN (fka $OXGN) Announces Results from Second Interim Analysis of CA4P Phase 2/3 FOCUS Study in Ovarian Cancer https://t.co/fmo1kWCMyO
August 16th 2017, 10:08am
Allstocknews @Allstocknews
$OXGN Mateon Therapeutics Announces Results from Second Interim Analysis of CA4P Phase 2/3 FOCUS Study in Pla From our Stock News Alerts App
August 16th 2017, 8:08am
MyAlliesTrading @MyAlliesTrading
$OXGN Mateon Therapeutics Completes Enrollment in Phase 2 Portion of FOCUS Study of CA4P for Platinum-Resistan... https://t.co/v7k9aZro6g
August 3rd 2017, 4:08pm
Allstocknews @Allstocknews
$OXGN Mateon Provides Corporate Update and Reports Second Quarter 2017 Financial Results From our Stock News Alerts App
August 2nd 2017, 4:08pm
teebizy @teebizy
RT @BioStocks: $MATN (fka $OXGN) Completes Enrollment in Phase 2 FOCUS Study of CA4P in Ovarian Cancer. Interim data read-outs in Aug, Sep…
August 1st 2017, 8:08am
BioStocks @BioStocks
$MATN (fka $OXGN) Completes Enrollment in Phase 2 FOCUS Study of CA4P in Ovarian Cancer. Interim data read-outs in Aug, Sep & Nov
August 1st 2017, 7:08am
Allstocknews @Allstocknews
$OXGN Mateon Therapeutics Completes Enrollment in Phase 2 Portion of FOCUS Study of CA4P for Platinum-Resista From our Stock News Alerts App
August 1st 2017, 7:08am
recervan @recervan
RT @BioStocks: $MATN (fka $OXGN) Announces Positive Initial Data from Fifth Cohort of Phase 1b Study of OXi4503 in AML https://t.co/4eDiYfa…
July 31st 2017, 7:07am
BioStocks @BioStocks
$MATN (fka $OXGN) Announces Positive Initial Data from Fifth Cohort of Phase 1b Study of OXi4503 in AML https://t.co/4eDiYfa7tz
July 31st 2017, 7:07am
Allstocknews @Allstocknews
$OXGN Mateon Therapeutics Announces Positive Initial Data from Fifth Cohort of Phase 1b Study of OXi4503 in R From our Stock News Alerts App
July 31st 2017, 7:07am
jeff90lx @jeff90lx
RT @Allstocknews: $OXGN Mateon Therapeutics Announces New Interim Preclinical Data on CA4P in Combination with Checkpoint Inhib From our St…
July 17th 2017, 11:07pm
Allstocknews @Allstocknews
$OXGN Mateon Therapeutics Announces New Interim Preclinical Data on CA4P in Combination with Checkpoint Inhib From our Stock News Alerts App
June 28th 2017, 7:06am

Contact © thinkBiotech LLC 2004 - 2017. All rights reserved.